Strs Ohio Acquires 68,887 Shares of Moderna, Inc. $MRNA

Strs Ohio increased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 802.5% in the 1st quarter, Holdings Channel reports. The fund owned 77,471 shares of the company’s stock after buying an additional 68,887 shares during the quarter. Strs Ohio’s holdings in Moderna were worth $3,936,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. MUFG Securities EMEA plc purchased a new position in shares of Moderna during the second quarter valued at approximately $28,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Moderna in the fourth quarter worth $31,000. Canton Hathaway LLC bought a new position in shares of Moderna during the first quarter valued at $31,000. Ameriflex Group Inc. increased its holdings in shares of Moderna by 3,775.0% during the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after acquiring an additional 1,208 shares in the last quarter. Finally, Cromwell Holdings LLC increased its holdings in shares of Moderna by 39.7% during the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after acquiring an additional 341 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of MRNA traded down $3.54 during mid-day trading on Tuesday, hitting $78.26. 1,495,918 shares of the company traded hands, compared to its average volume of 9,272,436. The stock has a market cap of $31.05 billion, a price-to-earnings ratio of -9.65 and a beta of 0.94. The stock has a 50-day moving average price of $54.08 and a two-hundred day moving average price of $48.58. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $85.60. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The firm had revenue of $389.00 million during the quarter, compared to analysts’ expectations of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The business’s quarterly revenue was up 260.2% on a year-over-year basis. During the same quarter last year, the business earned ($2.52) earnings per share. Equities analysts anticipate that Moderna, Inc. will post -6.51 earnings per share for the current year.

Insider Transactions at Moderna

In other news, Director Abbas Hussain sold 5,682 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $46.63, for a total transaction of $264,951.66. Following the completion of the sale, the director owned 12,066 shares of the company’s stock, valued at $562,637.58. This represents a 32.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Noubar Afeyan sold 9,263 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the transaction, the director owned 3,924 shares in the company, valued at $183,800.16. This trade represents a 70.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 125,088 shares of company stock valued at $6,193,713. Company insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on MRNA shares. The Goldman Sachs Group upped their price target on shares of Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Jefferies Financial Group restated a “hold” rating on shares of Moderna in a research note on Thursday, June 18th. Barclays lifted their target price on shares of Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a report on Thursday, April 2nd. UBS Group reiterated a “neutral” rating on shares of Moderna in a report on Tuesday, May 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a research report on Friday, June 12th. Two equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $37.60.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.